candesartan has been researched along with Complication, Postoperative in 9 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery." | 5.14 | ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009) |
| "Candesartan significantly reduced the development of coronary arteriosclerosis (intima/media ratio: 0." | 3.73 | The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy. ( Fukuda, D; Sata, M; Takamoto, S; Yamamoto, T, 2006) |
| "Candesartan has no additional effect on the rates of postoperative AF when added to ACEI." | 2.73 | Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. ( Dede, O; Duver, H; Ibrisim, E; Kapan, S; Ozaydin, M; Peker, O; Turker, Y; Varol, E, 2008) |
| "Proteinuria is common following kidney transplantation and affects more than 40% of kidney transplant patients per year." | 2.47 | Causes and consequences of proteinuria following kidney transplantation. ( G-Cosío, F; Suárez Fernández, ML, 2011) |
| "Although, prevention and treatment of angioedema have not been established, careful observation would be required." | 1.34 | [Case of facial edema and tongue swelling after aortic surgery in the lateral position]. ( Adachi, Y; Aoki, Y; Doi, M; Igarashi, H; Iwakiri, S; Katoh, T; Nakagawa, C; Sato, S; Uchisaki, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Cao, Y | 1 |
| Li, L | 1 |
| Liang, Y | 1 |
| Tian, X | 1 |
| Mo, N | 1 |
| Liu, Y | 1 |
| Li, M | 1 |
| Chui, D | 1 |
| Guo, X | 1 |
| Flesch, M | 1 |
| Knipp, S | 1 |
| Kessler, G | 1 |
| Geissler, HJ | 1 |
| Massoudy, P | 1 |
| Wilhelm, H | 1 |
| Philipp, T | 1 |
| Erdmann, E | 1 |
| Mariscalco, G | 1 |
| Dominici, C | 1 |
| Banach, M | 1 |
| Sala, A | 1 |
| Giordano, U | 1 |
| Cifra, B | 1 |
| Giannico, S | 1 |
| Turchetta, A | 1 |
| Calzolari, A | 1 |
| Suárez Fernández, ML | 1 |
| G-Cosío, F | 1 |
| Billings, FT | 1 |
| Balaguer, JM | 1 |
| C, Y | 1 |
| Wright, P | 1 |
| Petracek, MR | 1 |
| Byrne, JG | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Yamamoto, T | 1 |
| Sata, M | 1 |
| Fukuda, D | 1 |
| Takamoto, S | 1 |
| Ozaydin, M | 1 |
| Dede, O | 1 |
| Varol, E | 1 |
| Kapan, S | 1 |
| Turker, Y | 1 |
| Peker, O | 1 |
| Duver, H | 1 |
| Ibrisim, E | 1 |
| Iwakiri, S | 1 |
| Adachi, Y | 1 |
| Uchisaki, S | 1 |
| Aoki, Y | 1 |
| Nakagawa, C | 1 |
| Katoh, T | 1 |
| Igarashi, H | 1 |
| Doi, M | 1 |
| Sato, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The RAS, Fibrinolysis and Cardiopulmonary Bypass[NCT00607672] | Phase 4 | 111 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery. (NCT00607672)
Timeframe: From the start of surgery until postoperative day 3
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 28.6 |
| Ramipril (ACEI) | 23.8 |
| Candesartan (ARB) | 36.4 |
Blood loss over 24 hours as measured by chest tube output (NCT00607672)
Timeframe: First 24 hours after arrival in the intensive care unit
| Intervention | mL (Mean) |
|---|---|
| Placebo | 437 |
| Ramipril (ACEI) | 470 |
| Candesartan (ARB) | 511 |
(NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | days (Mean) |
|---|---|
| Placebo | 7.7 |
| Ramipril (ACEI) | 6.3 |
| Candesartan (ARB) | 8.1 |
New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 17.9 |
| Ramipril (ACEI) | 16.7 |
| Candesartan (ARB) | 27.3 |
The percentage of patients that were taken back to the operating room for re-exploration because of bleeding (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 3.6 |
| Ramipril (ACEI) | 8.3 |
| Candesartan (ARB) | 4.5 |
New onset neurological deficit with a duration of longer than 24 hours (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 7.1 |
| Ramipril (ACEI) | 4.2 |
| Candesartan (ARB) | 4.5 |
Percentage of patients that received blood product transfusion (NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Packed red blood cells | Plasma | Platelets | Cryoprecipitate | |
| Candesartan (ARB) | 2.7 | 31.8 | 22.7 | 4.5 |
| Placebo | 67.9 | 60.7 | 46.4 | 7.1 |
| Ramipril (ACEI) | 62.5 | 29.2 | 29.2 | 4.2 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 4.21 | 749.56 | 22.55 | 14.26 |
| Placebo | 4.45 | 461.90 | 30.70 | 16.74 |
| Ramipril (ACEI) | 5.36 | 815.74 | 26.89 | 14.59 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 6.44 | 144.76 | 218.16 | 243.72 |
| Placebo | 6.29 | 116.04 | 224.96 | 166.96 |
| Ramipril (ACEI) | 9.33 | 167.51 | 172.65 | 144.67 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 13.38 | 76.76 | 37.11 | 37.77 |
| Placebo | 16.18 | 66.44 | 46.18 | 34.39 |
| Ramipril (ACEI) | 11.86 | 80.07 | 37.39 | 28.06 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 18.28 | 24.19 | 49.10 | 21.70 | 13.4 |
| Placebo | 15.14 | 20.43 | 39.69 | 31.83 | 21.59 |
| Ramipril (ACEI) | 16.25 | 19.41 | 41.62 | 26.27 | 17.33 |
To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 11.97 | 24.89 | 31.47 | 15.75 | 12.89 |
| Placebo | 14.36 | 27.65 | 34.56 | 20.25 | 16.56 |
| Ramipril (ACEI) | 14.05 | 36.67 | 41.11 | 17.10 | 12.49 |
(NCT00607672)
Timeframe: From the end of cardiopulmonary bypass until arrival in intensive care unit
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Dobutamine | Mlrinone | Norepinephrine | Epinephrine | |
| Candesartan (ARB) | 27.3 | 22.7 | 95.5 | 13.6 |
| Placebo | 35.7 | 25.0 | 85.7 | 7.1 |
| Ramipril (ACEI) | 29.2 | 25.0 | 79.2 | 4.3 |
1 review available for candesartan and Complication, Postoperative
| Article | Year |
|---|---|
Causes and consequences of proteinuria following kidney transplantation.
Topics: Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Endothelium, Vascular; Graft Rejection; | 2011 |
3 trials available for candesartan and Complication, Postoperative
| Article | Year |
|---|---|
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2009 |
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2012 |
Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2008 |
5 other studies available for candesartan and Complication, Postoperative
| Article | Year |
|---|---|
Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: comment on: Mehmet Ozaydin et al. "Effect of renin-angiotensin aldosterone system blockers on postoperative atrial fibrillation".
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillati | 2010 |
Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation.
Topics: Adolescent; Antihypertensive Agents; Aortic Coarctation; Atenolol; Benzimidazoles; Biphenyl Compound | 2009 |
The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteriosclerosis; Benzimidazoles; Biphenyl Compoun | 2006 |
[Case of facial edema and tongue swelling after aortic surgery in the lateral position].
Topics: Aged; Anesthesia; Angioedema; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benz | 2007 |